Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy

American Journal of Nephrology

Volumn 43, Issue 2, 2016, Pages 129-140

  Wei, Shi Yao ^a   Wang, Yu Xiao ^a   Li, Jian Si ^a   Zhao, Shi Lei ^a   Diao, Tian Tian ^a   Waang, Yu ^a   Wang, Chang ^a   Qin, Ying ^a   Cao, Yang ^a   Wei, Qiuju ^a   Li, Bing ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Anti PLA2 R antibody; Idiopathic membranous nephropathy; Proteinuria

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; ANTIBODY; BIOLOGICAL MARKER; PHOSPHOLIPASE A2 RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHINESE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; BLOOD; CHEMISTRY; GLOMERULUS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SURVIVAL RATE;

ADULT; ANTIBODIES; BIOMARKERS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; RECEPTORS, PHOSPHOLIPASE A2; SURVIVAL RATE;

EID: 84969584461     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000445361     Document Type: Article

References (32)

1. Zhou FD, Shen HY, Chen M, Liu G, Zou WZ, Zhao MH, Wang HY: The renal histopatho-logical spectrum of patients with nephrotic syndrome: an analysis of 1523 patients in a single Chinese centre. Nephrol Dial Transplant 2011; 26:3993-3997.
2. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000; 35:157-165.
3. Beck LH Jr, Salant DJ: Membranous nephrop-athy: recent travels and new roads ahead. Kidney Int 2010; 77:765-770.
4. Ronco P, Debiec H: Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010; 21:564-569.
5. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Tracht-man H, Waldman M: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013; 62:403-441.
6. Waldman M, Austin HA 3rd: Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1617-1630.
7. Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, Baltar J, Fernandez-Fresnedo G, Martin C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernandez-Juarez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernandez-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idio-pathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704.
8. Glassock RJ: Human idiopathic membranous nephropathy-A mystery solved? N Engl J Med 2009; 361:81-83.
9. Beck LH Jr, Bonegio RG, Lambeau G, et al: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropa-thy. N Engl J Med 2009; 361:11-21.
10. Hoxha E, Kneissler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA: Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82:797-804.
11. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Anti-phospholipase A2 receptor antibody in membranous nephropa-thy. J Am Soc Nephrol 2011; 22:1137-1143.
12. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H: Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 2013; 28:1839-1844.
13. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cat-tran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543-1550.
14. Hoxha E, Thiele I, Zahner G, Panzer U, Har-endza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropa-thy. J Am Soc Nephrol 2014; 25:1357-1366.
15. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pelle T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G: An-ti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015; 26:2545-2558.
16. Brenchley PE: Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase A2 receptor autoantibodies. J Am Soc Nephrol 2015; 26:2308-2311.
17. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idio-pathic membranous nephropathy. Kidney Int 2013; 83:940-948.
18. Li X, Lv R, He Q, Li H, Du XY, Lin WQ, Li Q, He XL: Early initiation of tacrolimus or cyclo-phosphamide therapy for idiopathic membranous nephropathy with severe protein-uria. J Nephrol 2008; 21:584-591.
19. Praga M, Barrio V, Juarez GF, Luno J: Tacro-limus monotherapy in membranous ne-phropathy: a randomized controlled trial. Kidney Int 2007; 71:924-930.
20. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH: Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76:307-317.
21. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26:2526-2532.
22. Peng L, Wei SY, Li LT, He YX, Li B: Comparison of different therapies in high-risk patients with idiopathic membranous nephrop-athy. J Formos Med Assoc 2016; 115:11-18.
23. Ponticelli C, Glassock RJ: Glomerular diseases: membranous nephropathy-A modern view. Clin J Am Soc Nephrol 2014; 9:609-616.
24. van den Brand JA, Hofstra JM, Wetzels JF: Prognostic value of risk score and urinary markers in idiopathic membranous nephrop-athy. Clin J Am Soc Nephrol 2012; 7:1242-1248.
25. Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomeru-lonephritis Registry: The natural history of the non-nephrotic membranous nephropa-thy patient. Clin J Am Soc Nephrol 2009; 4: 1417-1422.
26. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD: Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013; 26:709-715.
27. Li Y, Zhou A, Lv G, Li P, Chen S, Li J, Wen X, Wu Z, Zhang S, Wang J, Zhang F, Li Y: Single-nucleotide polymorphisms in the PLA2R1 gene are associated with systemic lupus erythe-matosus and lupus nephritis in a Chinese Han population. Immunol Res 2016; 64: 324-328.
28. Debiec H, Ronco P: PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364: 689-690.
29. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, De-bayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371: 2277-2287.
30. Tang H, Duong PH, Waldman MA, Zhu Q: Intramolecular epitope spreading in phos-pholipase A2 receptor in IMN. J Am Soc Nephrol 2015; 26:589A.
31. Singh AK: Proteolytic machinery of glomeru-lar epithelial cells against IgG. Biochem Bio-phys Res Commun 1992; 186:639-644.
32. Makino H, Lelongt B, Kanwar YS: Nephrito-genicity of proteoglycans. III. Mechanism of immune deposit formation. Kidney Int 1988; 34:209-219.